Furthermore, a placebo, randomized, double-blind clinical trial showed a trend to reduction of symptoms in depressive patients treated during 8 weeks with BTRX-246040 ( Post et al., 2016 ), a highly potent and selective NOP receptor antagonist ( Ferrari et al., 2020 ).
← all excerpts
Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice.
1
—
—